ALX ONCOLOGY HOLDINGS INC Number of Operating Segments
ALX ONCOLOGY HOLDINGS INC (ALXO) reported Number of Operating Segments of 1 Segment for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Segment Reporting
us-gaap:NumberOfOperatingSegments · last filed 2026-08-06
- ALX ONCOLOGY HOLDINGS INC number of operating segments for the quarter ending 2026-03-31 was 1.00 Segment, a 0.00% change year-over-year.
- ALX ONCOLOGY HOLDINGS INC number of operating segments for the quarter ending 2025-03-31 was 1.00 Segment.
- ALX ONCOLOGY HOLDINGS INC number of operating segments for fiscal 2025 was 1.00 Segment, a 0.00% change from fiscal 2024.
- ALX ONCOLOGY HOLDINGS INC number of operating segments for fiscal 2024 was 1.00 Segment, a 0.00% change from fiscal 2023.
- ALX ONCOLOGY HOLDINGS INC number of operating segments for fiscal 2023 was 1.00 Segment, a 0.00% change from fiscal 2022.
- ALX ONCOLOGY HOLDINGS INC number of operating segments for fiscal 2022 was 1.00 Segment, a 0.00% change from fiscal 2021.
| Period end | Number of Operating Segments 3 month | Number of Operating Segments 6 month | Number of Operating Segments 9 month | Number of Operating Segments 12 month |
|---|---|---|---|---|
| 2026-06-30 | 1.00 Segment 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | 1.00 Segment 10-Q · filed 2026-05-08 | |||
| 2025-12-31 | 1.00 Segment 10-K · filed 2026-03-09 | |||
| 2025-09-30 | 1.00 Segment 10-Q · filed 2025-11-07 | |||
| 2025-06-30 | 1.00 Segment 10-Q · filed 2025-08-12 | |||
| 2025-03-31 | 1.00 Segment 10-Q · filed 2025-05-08 | |||
| 2024-12-31 | 1.00 Segment 10-K · filed 2025-03-06 | |||
| 2023-12-31 | 1.00 Segment 10-K · filed 2024-03-07 | |||
| 2022-12-31 | 1.00 Segment 10-K · filed 2023-03-09 | |||
| 2021-12-31 | 1.00 Segment 10-K · filed 2022-02-28 | |||
| 2020-12-31 | 1.00 Segment 10-K · filed 2021-03-18 | |||
| 2020-09-30 | 1.00 Segment 10-Q · filed 2020-11-12 | |||
| 2020-06-30 | 1.00 Segment 10-Q · filed 2020-08-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |